JP6152391B2 - セラノスティクスにおいて有用なポリマーナノ粒子 - Google Patents

セラノスティクスにおいて有用なポリマーナノ粒子 Download PDF

Info

Publication number
JP6152391B2
JP6152391B2 JP2014559046A JP2014559046A JP6152391B2 JP 6152391 B2 JP6152391 B2 JP 6152391B2 JP 2014559046 A JP2014559046 A JP 2014559046A JP 2014559046 A JP2014559046 A JP 2014559046A JP 6152391 B2 JP6152391 B2 JP 6152391B2
Authority
JP
Japan
Prior art keywords
polymer
nanoparticles
starch
appendix
pmaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014559046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512978A5 (enrdf_load_stackoverflow
JP2015512978A (ja
Inventor
ユー ウー，シャオ
ユー ウー，シャオ
シャルヴィリ，アリレザ
ツァイ，ピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2015512978A publication Critical patent/JP2015512978A/ja
Publication of JP2015512978A5 publication Critical patent/JP2015512978A5/ja
Application granted granted Critical
Publication of JP6152391B2 publication Critical patent/JP6152391B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Graft Or Block Polymers (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
JP2014559046A 2012-03-02 2013-03-04 セラノスティクスにおいて有用なポリマーナノ粒子 Active JP6152391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605995P 2012-03-02 2012-03-02
US61/605,995 2012-03-02
PCT/CA2013/000203 WO2013127004A1 (en) 2012-03-02 2013-03-04 Polymeric nanoparticles useful in theranostics

Publications (3)

Publication Number Publication Date
JP2015512978A JP2015512978A (ja) 2015-04-30
JP2015512978A5 JP2015512978A5 (enrdf_load_stackoverflow) 2016-04-21
JP6152391B2 true JP6152391B2 (ja) 2017-06-21

Family

ID=49081494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559046A Active JP6152391B2 (ja) 2012-03-02 2013-03-04 セラノスティクスにおいて有用なポリマーナノ粒子

Country Status (7)

Country Link
US (2) US10233277B2 (enrdf_load_stackoverflow)
EP (1) EP2820070B1 (enrdf_load_stackoverflow)
JP (1) JP6152391B2 (enrdf_load_stackoverflow)
CN (1) CN104470975B (enrdf_load_stackoverflow)
CA (1) CA2865925C (enrdf_load_stackoverflow)
SG (1) SG11201405407WA (enrdf_load_stackoverflow)
WO (1) WO2013127004A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780164B2 (en) 2014-04-03 2020-09-22 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
AU2016220103A1 (en) * 2015-02-18 2017-10-05 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
AU2016302254B2 (en) 2015-08-03 2019-09-12 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
CN105732901B (zh) * 2016-04-22 2018-02-02 广西大学 一种木薯渣磁性微球及其制备方法
CN108003286A (zh) * 2017-12-15 2018-05-08 北京思如诺科技有限公司 一种用于肿瘤放射性诊疗的共聚物及其制备方法和应用
EP3713571A4 (en) 2018-01-12 2021-08-25 ENB Therapeutics, Inc. DEUTERATED COMPOUNDS, COMPOSITIONS AND TREATMENT METHODS FOR CANCERS ASSOCIATED WITH ETBR ACTIVATION
CN110960508B (zh) * 2019-11-13 2021-11-23 湖北大学 一种具有抗蛋白吸附和靶向能力的淀粉纳米粒子及其制备方法
US20210361570A1 (en) * 2020-05-19 2021-11-25 Mcmaster University In situ gelling polysaccharide-based nanoparticle hydrogel compositions, and methods of use thereof
JPWO2022024754A1 (enrdf_load_stackoverflow) * 2020-07-27 2022-02-03
WO2024254703A1 (en) * 2023-06-15 2024-12-19 Qurcan Therapeutics Inc. Intelligent polymer-lipid based nano drug delivery system to improve the bbb-penetration by dual active brain targeting strategies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57138411A (en) 1981-02-16 1982-08-26 Nippon Denso Co Ltd Air intake controller for car air conditioner
US4690996A (en) * 1985-08-28 1987-09-01 National Starch And Chemical Corporation Inverse emulsions
GB9411080D0 (en) 1994-06-02 1994-07-20 Unilever Plc Treatment
AU3243300A (en) 1999-02-23 2000-09-14 Isis Pharmaceuticals, Inc. Multiparticulate formulation
CN1388169A (zh) * 2002-07-26 2003-01-01 张夫道 纳米级废弃塑料－淀粉混聚物生产方法及应用
NO20035745D0 (no) 2003-12-19 2003-12-19 Amersham Health As Prosess
CN1709935A (zh) * 2005-06-17 2005-12-21 天津大学 淀粉接枝聚丙烯酰胺及其衍生物反相乳液的制备方法
WO2009049089A1 (en) * 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
ES2685464T3 (es) * 2008-04-04 2018-10-09 The Regents Of The University Of California Nanopartículas magnéticas funcionalizadas y métodos de uso de las mismas
EP2310519A2 (de) * 2008-08-07 2011-04-20 Bioscreen e.K. Verfahren zur epoxidation ungesättigter fettsäuren und anschliessender kopplung dieser unter verwendung einer lipase
WO2010084060A1 (en) 2009-01-21 2010-07-29 Basf Se Starch copolymers and nanoparticles thereof for drug delivery systems
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents

Also Published As

Publication number Publication date
EP2820070A4 (en) 2016-03-09
US10233277B2 (en) 2019-03-19
WO2013127004A1 (en) 2013-09-06
EP2820070A1 (en) 2015-01-07
SG11201405407WA (en) 2014-10-30
US11155664B2 (en) 2021-10-26
US20150132384A1 (en) 2015-05-14
US20190233567A1 (en) 2019-08-01
JP2015512978A (ja) 2015-04-30
CN104470975B (zh) 2018-02-27
CN104470975A (zh) 2015-03-25
EP2820070B1 (en) 2023-07-26
CA2865925A1 (en) 2013-09-06
CA2865925C (en) 2021-06-01

Similar Documents

Publication Publication Date Title
JP6152391B2 (ja) セラノスティクスにおいて有用なポリマーナノ粒子
Zhou et al. Synthesis and characterization of PEGylated polyethylenimine-entrapped gold nanoparticles for blood pool and tumor CT imaging
US9901616B2 (en) Apoptosis-targeting nanoparticles
Shen et al. Dendrimer-based organic/inorganic hybrid nanoparticles in biomedical applications
Sun et al. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD)
Tran et al. Design of iron oxide nanoparticles decorated oleic acid and bovine serum albumin for drug delivery
Zhuang et al. Laponite-polyethylenimine based theranostic nanoplatform for tumor-targeting CT imaging and chemotherapy
Chen et al. Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging
Sun et al. Gadolinium-loaded poly (N-vinylcaprolactam) nanogels: synthesis, characterization, and application for enhanced tumor MR imaging
Saravanakumar et al. Polysaccharide-based nanoparticles: a versatile platform for drug delivery and biomedical imaging
Hwang et al. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles
Srikar et al. Polymeric nanoparticles for molecular imaging
US20100168044A1 (en) Superparamagnetic nanoparticle encapsulated with stimuli responsive polymer for drug delivery
Lian et al. Core cross-linked poly (ethylene glycol)-graft-Dextran nanoparticles for reduction and pH dual responsive intracellular drug delivery
Pei et al. Design of Janus-like PMMA-PEG-FA grafted fluorescent carbon dots and their nanoassemblies for leakage-free tumor theranostic application
Song et al. Core–shell tecto dendrimers enable enhanced tumor MR imaging through an amplified EPR effect
Huang et al. Design and application of dextran carrier
Gardikis et al. Dendrimers and the development of new complex nanomaterials for biomedical applications
Agarwal et al. Cationized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug
Khatik et al. Integrin αvβ3 receptor overexpressing on tumor-targeted positive MRI-guided chemotherapy
Chen et al. A dual-targeting nanocarrier based on modified chitosan micelles for tumor imaging and therapy
CN108379241B (zh) 胆甾醇疏水改性普鲁兰-多奈哌齐-聚山梨酯80纳米粒子及制备和应用
Shi et al. Amphiphilic copolymer and TPGS mixed magnetic hybrid micelles for stepwise targeted co-delivery of DOX/TPP–DOX and image-guided chemotherapy with enhanced antitumor activity in liver cancer
Shen et al. Modular assembly of drug and monodisperse SPIONs for superior magnetic and T2-imaging performance
Sambi et al. Advancements in polymer science:‘smart’drug delivery systems for the treatment of cancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170529

R150 Certificate of patent or registration of utility model

Ref document number: 6152391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250